Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Odyssey Group Intl Inc
(OP:
ODYY
)
0.0457
UNCHANGED
Streaming Delayed Price
Updated: 2:24 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Odyssey Group Intl Inc
< Previous
1
2
3
Next >
Odyssey Health Closes Asset Sale of its Neurological Drug Technology Pipeline Including Concussion Drug Candidate with Oragenics, Inc.
January 02, 2024
Via
ACCESSWIRE
Odyssey Health, Inc. Gains Shareholder Approval for Asset Sale with Oragenics, Inc.
December 12, 2023
Via
ACCESSWIRE
Odyssey Health, Inc, Selects Syneos Health to Support Investigational New Drug Application for Treatment of Concussion
November 16, 2023
Via
ACCESSWIRE
Odyssey Health, Inc. to Provide Company Update and Webcast for Shareholders
November 15, 2023
Via
ACCESSWIRE
Odyssey Health, Inc. Provides Update on Asset Purchase Agreement with Oragenics, Inc.
October 18, 2023
Via
ACCESSWIRE
Oragenics to Acquire Odyssey Health’s Neurological Drug Technology Pipeline Including Concussion Drug Candidate
October 05, 2023
From
Oragenics, Inc.
Via
Business Wire
Odyssey Health Inc. Begins Trading on the OTCQB
October 04, 2023
Via
ACCESSWIRE
Odyssey Health, Inc. Presents Concussion Treatment Data at the Military Health System Research Symposium - MHSRS
August 23, 2023
Via
ACCESSWIRE
Odyssey Health, Inc. Presents Data at the Special Operations Medical Association - Scientific Assembly
June 08, 2023
Via
ACCESSWIRE
Odyssey Health, Inc. Preparing for a Phase II Pharmaceutical Concussion Treatment
March 30, 2023
McapMediaWire -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on creating unique, life-enhancing medical products, is developing a novel...
Via
TheNewswire.com
Odyssey Health, Inc. (ODYY) To Give Corporate Update at Scheduled Annual Meeting of Stockholders in January 2023
December 01, 2022
Via
Investor Brand Network
Topics
Animal Testing
Exposures
Animal Testing
BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Reports on Concussion Drug Progress, Provides Corporate Update
November 23, 2022
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
World Cup 2022 to Feature New Protocol to Respond to Suspected Concussions
November 22, 2022
Via
Investor Brand Network
Odyssey Health, Inc. (ODYY) Expands Executive Team of New Subsidiary in Strategic Move to Strengthen Marketing of Concussion, Neurological Therapies
November 21, 2022
Via
Investor Brand Network
Surgical Team in Spain Completes First-Ever Intestinal Transplant
November 17, 2022
Via
Investor Brand Network
BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Announces Upcoming Annual Meeting of Stockholders
November 15, 2022
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Odyssey Health, Inc. (ODYY) Focuses on Medical Devices Market with US Patent Application on Breath-Propelled Intranasal Delivery Device
November 14, 2022
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Study Finds Iron Causes Chronic Heart Failure in Heart Attack Survivors
November 09, 2022
Via
Investor Brand Network
New Pharmaceutical Subsidiary Geared to Aid Odyssey Health, Inc. (ODYY) Development of Novel Solutions for Brain Related Medical Treatments
November 07, 2022
Via
Investor Brand Network
Experts Concerned That Concussion Protocols Don’t Factor in Women
November 04, 2022
Via
Investor Brand Network
BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Announces Expansion of Executive Team
November 03, 2022
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Files for Patent Protection on Novel Breath-Propelled Intranasal Brain-Drug Delivery Device
November 01, 2022
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Pleased with Safety Profile of Its PRV-002 Concussion Treatment
October 31, 2022
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
New Research Uncovers Racial Disparities in Treatment of Heart Failure
October 31, 2022
Via
Investor Brand Network
BioMedNewsBreaks – Odyssey Health Inc.’s (ODYY) PRV-002 Designed to Expedite Return to Work, Play Following Concussive Episode
October 26, 2022
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
New Experimental Drug May Reverse Brain Damage Caused by Concussions
October 24, 2022
Via
Investor Brand Network
Odyssey Health, Inc. (ODYY) Updates Progress of its Concussion Drug Development Program; Communicating with the FDA for permission to start phase II clinical trial of its PRV-002 Drug Candidate
October 18, 2022
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
BioMedNewsBreaks – Odyssey Health Inc.’s (ODYY) PRV-002 Designed to Mitigate Short- and Long-Term Effects of mTBI
October 17, 2022
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Researchers Develop AI Tool That Scans Retina, Detects Heart Disease in One Minute
October 17, 2022
Via
Investor Brand Network
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Odyssey Health, Inc. (ODYY) Seeking to Provide Solution to Concussion-Prone Military and NFL with Development of PRV-002 Drug Candidate
October 14, 2022
Via
Investor Brand Network
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.